Bapineuzumab for mild to moderate Alzheimer's disease: a meta-analysis of randomized controlled trials.

ABSTRACT:

Background

Alzheimer's disease (AD) is a globally prevalent neurodegenerative condition, clinically characterized by progressive memory loss and gradual impairment of cognitive functions. Bapineuzumab is a fully humanized monoclonal antibody that binds to neurotoxic amyloid proteins in the brain, enhancing their clearance. We performed this systematic review and meta-analysis to evaluate the safety and efficacy of bapineuzumab in patients with mild to moderate Alzheimer's disease.

Methods

We performed a web-based literature search of PubMed, Ovid, EBSCO, Scopus, Embase, Cochrane CENTRAL, and web of science using the relevant keywords. Data were extracted from eligible records and pooled as mean difference (MD) or risk ratio (RR) values with their 95% confidence interval (CI)

SUBMITTER: Abushouk AI 

PROVIDER: S-EPMC5381133 | biostudies-literature | 2017 Apr

REPOSITORIES: biostudies-literature